Comparative Pharmacology
Head-to-head clinical analysis: OXTRIPHYLLINE versus SYNOPHYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXTRIPHYLLINE versus SYNOPHYLATE.
OXTRIPHYLLINE vs SYNOPHYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular cAMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
None Documented
None Documented
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Clinical Note
moderateOxtriphylline + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Acemetacin
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Clotrimazole
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Clotrimazole can be decreased when combined with Oxtriphylline."